Table 2.
Characteristics of eligible studies evaluating the effect of phase I and phase II metabolic enzyme polymorphisms on risk of Barrett’s esophagus
| Study (first author [year published], country, study time period, reference no.) |
Case ascertainment | Sample size (case/control) |
Controls ascertainment | SNPs | Cases | Controls | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | Race (%) | Men (%) | Age | Race (%) | Men (%) | |||||
| van Lieshout (1999), Netherlands, 4-year span20 |
Hospital based | 98/247 | Healthy, source–unknown, unmatched |
CYP1A1 (MspI) CYP1A1 (Ile462Val), GSTM1 (null), GSTP1 (Ile105Val), GSTT1 (null) |
Mean = 64, SD 2 | White (100) | (86) | Mean = 52, SD 2 |
White (100) | Unknown (40) |
| Casson (2006), Canada, 2001–200313 |
Hospital based | 125/95 | Healthy, clinic based, freq. match but unknown on what |
GSTM1(null), GSTP1 (Ile105Val), GSTT1 (null), EPHX1 (exon 3), EPHX1 (exon 4) |
<50years = 4%, ≥50years = 96% |
White (100) | 50 (89) | <50 years = 38% ≤50years = 62% |
White (100) | 64 (67) |
| Kala (2007), Czech Republic, Unknown17 |
Hospital based | 22/173 | Healthy, clinic based, age, sex and smoking, matched |
GSTM1 (null), GSTP1 (Ile105Val), GSTT1 (null) |
Mean = 46.4, SD 12.7 |
White (100) | 18 (82) | Mean = 44.7, SD 10.7 |
White (100) | 107 (62) |
| Murphy (2007), Ireland18 | Hospital based | 189/223 | Healthy, population based, | GSTP1 (Ile105Val) | Mean = 62.2 (24–85) | White (100) | 156 (83) | Mean = 64.4 (35–86) |
White (100) | 184 (83) |
| di Martino (2007), UK14 | Hospital based | 200/94 | Symptomatic but disease free, hospital based, unmatched |
NQ01 (Pro609Ser) | Mean = 65 (25–97) | Unknown | 148 (741) | Mean = 56 (29–88) |
Unknown | 42 (45) |
SD, standard deviation; SNPs, single-nucleotide polymorphisms.